Theravance Biopharma (TBPH) Stock Rating Lowered by ValuEngine
ValuEngine cut shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a sell rating in a report issued on Wednesday morning.
TBPH has been the topic of several other research reports. Needham & Company LLC reiterated a buy rating on shares of Theravance Biopharma in a research note on Tuesday, December 5th. BidaskClub upgraded shares of Theravance Biopharma from a strong sell rating to a sell rating in a research note on Saturday, January 20th. Cantor Fitzgerald reiterated a buy rating and issued a $55.00 price target on shares of Theravance Biopharma in a research note on Tuesday, November 7th. Finally, Leerink Swann boosted their price target on shares of Theravance Biopharma from $45.00 to $48.00 and gave the stock an outperform rating in a research note on Thursday, February 8th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Theravance Biopharma presently has an average rating of Hold and a consensus target price of $42.00.
Shares of Theravance Biopharma (NASDAQ TBPH) traded up $0.07 during mid-day trading on Wednesday, reaching $28.61. 267,695 shares of the company’s stock traded hands, compared to its average volume of 220,718. Theravance Biopharma has a 1-year low of $22.90 and a 1-year high of $43.44. The company has a debt-to-equity ratio of 1.94, a quick ratio of 5.79 and a current ratio of 6.05.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.